HRS-5091

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameHRS-5091
Drug Alias NameHRS-5091
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHBV DNA Polymerase inhibitors
TargetsHBV DNA Polymerase
Therapy Area/IndicationsHepatitis B, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesJiangsu Hengrui Medicine Co LtdSuzhou Suncadia Biopharmaceuticals Co LtdShanghai Hengrui Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesChengdu Xinyue Pharmaceutical Co LtdShanghai Hengrui Pharmaceutical Co LtdSuzhou Suncadia Biopharmaceuticals Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsHepatitis B, Chronic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A